Vitamin B6 deficiency in patients with a clinical syndrome including the carpal tunnel defect. Biochemical and clinical response to therapy with pyridoxine.
Ten individuals having a severe clinical status associated with the carpal tunnel syndrome were selected for treatment with pyridoxine. The status of vitamin B6, as pyridoxal phosphate, was determined by the specific activities of the glutamic oxaloacetic transaminase of the erythrocytes (EGOT). Before treatment, the patients showed a deficiency of vitamin B6 as determined by 1) a comparison of the specific activities of EGOT with those of a control group (P less than 0.001); and 2) a differential assay based upon the principle of unsaturation and saturation of a Coenzyme-Apoenzyme System (CAS), as applied to EGOT. These patients were treated with pyridoxine, and the specific activities of EGOT were determined after 2 and 4 weeks. Not only was there a disappearance of the deficiency of pyridoxal phosphate, but the level of EGOT activity increased 55-68% during 2-4 weeks, respectively. More apoenzyme was apparently biosynthesized, because the specific activities were significantly higher than before therapy (P less than 0.001/4 wks). Clinical evaluation showed a great improvement in their status, and anticipated surgery for some of the patients became unnecessary. It is concluded that patients with a severe syndrome including the carpal tunnel defect have a deficiency of vitamin B6, and that both the syndrome and the deficiency are relived by therapy with pyridoxine.
D000328:Adult; D001219:Aspartate Aminotransferases / Q000378:metabolism; D002349:Carpal Tunnel Syndrome / Q000188:drug therapy*; D004912:Erythrocytes / Q000201:enzymology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009784:Occupational Diseases / Q000209:etiology; D011736:Pyridoxine / Q000627:therapeutic use*; D013997:Time Factors; D026681:Vitamin B 6 Deficiency / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology
D001219:Aspartate Aminotransferases; D011736:Pyridoxine